What is the appropriate fosfomycin dosing for a patient with an estimated glomerular filtration rate of 48 mL/min/1.73 m² (moderate renal impairment)?

Fosfomycin Dosing for GFR 48 mL/min/1.73 m²

For a patient with GFR 48 mL/min/1.73 m² (CKD Stage 3a), the standard oral fosfomycin dose of 3 grams as a single dose requires no adjustment and can be administered safely.

Rationale Based on FDA Label and Pharmacokinetic Data

The FDA label for oral fosfomycin tromethamine explicitly addresses renal impairment 111. While the label notes that renal impairment significantly decreases fosfomycin excretion and increases elimination half-life, no specific dosage adjustment recommendations are provided for mild to moderate renal impairment. The pharmacokinetic data show:

• In patients with creatinine clearances ranging from 54 mL/min to 7 mL/min, the elimination half-life increased from 11 hours to 50 hours
• Urinary recovery decreased from 32% to 11% with worsening renal function
• However, therapeutic urinary concentrations are still achieved and maintained

Clinical Evidence Supporting Standard Dosing

A key study in elderly nursing home patients with impaired renal function (mean creatinine clearance 40 mL/min—similar to your patient's GFR of 48) demonstrated that after a single 3-gram oral dose 2:

• Urinary fosfomycin concentrations remained well above the MIC for common uropathogens for at least 48 hours
• First 12-hour urinary concentrations averaged 1,383 mg/L (range 314-4,200 mg/L)
• Concentrations at 36-48 hours were still 165 mg/L (range 65-365 mg/L)
• These levels far exceed the MIC breakpoint of ≤64 mg/L for susceptible organisms

Importantly, urinary concentrations in patients with renal impairment were actually higher than those reported in healthy young subjects after 24 hours 2, suggesting that the reduced renal clearance paradoxically maintains therapeutic drug levels in the urine for longer periods.

Key Clinical Considerations

Why No Dose Reduction is Needed

1. Fosfomycin is indicated for uncomplicated cystitis, where the site of action is the urinary tract
2. Adequate urinary concentrations are maintained even with reduced renal excretion
3. The prolonged elimination half-life in renal impairment actually extends the duration of therapeutic urinary levels
4. The single-dose regimen minimizes accumulation concerns

Important Caveats

• This guidance applies specifically to oral fosfomycin for uncomplicated urinary tract infections
• For intravenous fosfomycin (used for systemic infections), different considerations apply—recent data suggest dose adjustments based on renal function and dialysis status 3
• Avoid metoclopramide co-administration, as it significantly lowers fosfomycin serum concentrations and urinary excretion 11
• The patient should take fosfomycin on an empty stomach for optimal absorption (bioavailability 37% fasting vs. 30% fed) 1

Monitoring

• No specific monitoring is required for a single-dose oral regimen
• Standard clinical follow-up for treatment response is appropriate
• If symptoms persist beyond 2-3 days, consider alternative diagnosis or resistant organism

Context Within Broader CKD Management

Your patient's GFR of 48 mL/min/1.73 m² places them in CKD Stage 3a (moderate decrease in GFR: 45-59 mL/min/1.73 m²) 45. While many antimicrobials require dose adjustment at this level of renal function (e.g., fluoroquinolones at GFR <15, macrolides at GFR <30) 44, oral fosfomycin's unique pharmacokinetic profile and urinary concentration-dependent efficacy make it an exception to this general rule.

Bottom line: Administer the standard 3-gram single oral dose of fosfomycin without modification for this patient with GFR 48 mL/min/1.73 m².